NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
February 15, 2005 • Volume 2 / Number 7 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
NCI Announces Senior Leadership Changes

Director's Update
CTWG to Unveil Draft Proposal and Invite Continuing Input at NCAB

Special Report
Smoking Cessation Program Improves Overall and Lung Cancer Survival

Cancer Research Highlights
APC Trial Safety Data Published

Zinc Deficiency and Risk of Esophageal Cancer

Two Studies Find Cause of Pediatric Brain Cancer

Circadian Rhythms May Influence Chemo Toxicity

Neoadjuvant Therapy and Surgery in Breast Cancer Treatment

Featured Clinical Trial
Treating Kidney Tumors in Patients With Von Hippel-Lindau Disease

Funding Opportunities

NCI Gold Star Awards

Notes
NCI Releases Software for Sharing Microarray Data

NCI Workshop Identifies Strategies and Priorities for Biomarker Discovery

Langer to Present at NCI Nanotechnology Seminar Series

Community Update
NCI, FDA Sponsor Biomarker Meeting

Bulletin Archive

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Featured Article

NCI Announces Senior Leadership Changes

Speaking at an "all-hands" meeting of National Cancer Institute (NCI) employees today, NCI Director Dr. Andrew C. von Eschenbach announced several changes among senior NCI leadership, including the departures of a deputy director and the director of the Center for Cancer Research (CCR).

Dr. Karen H. Antman, the deputy director for translational and clinical sciences, has accepted a job as provost of the Boston University Medical Campus and dean of the School of Medicine. And CCR Director Dr. J. Carl Barrett has taken a position with the Novartis Institutes for Biomedical Research as Global Head of Oncology Biomarkers.

"Losing these two individuals with respect to their leadership is, for us, going to be a great loss," Dr. von Eschenbach said. "But, like all great institutions, we have great people who step up." CCR Principal Deputy Director Dr. Robert Wiltrout, he announced, will become the new director of CCR.  Read more  

Director's Update

CTWG to Unveil Draft Proposal and Invite Continuing Input at NCAB

The Clinical Trials Working Group (CTWG), a panel of 40 clinical trialists, advocates, and government representatives established in 2004 by NCI Director Dr. Andrew C. von Eschenbach to evaluate the national cancer clinical research enterprise, will report draft recommendations to the National Cancer Advisory Board (NCAB) this week.

As part of its transparent, inclusive approach to increasing cancer clinical trials efficiency, decreasing redundancy and administrative burdens, and better coordinating activities to enhance the development and delivery of the best therapies to people with cancer, CTWG welcomes public comment on the draft recommendations. Final  Read more  

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov